<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Lancet</journal-id>
      <journal-title-group>
        <journal-title>Lancet</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0140-6736</issn>
      <issn pub-type="epub">1474-547X</issn>
      <publisher>
        <publisher-name>Lancet Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3156981</article-id>
      <article-id pub-id-type="pmid">21803414</article-id>
      <article-id pub-id-type="publisher-id">LANCET60872</article-id>
      <article-id pub-id-type="doi">10.1016/S0140-6736(11)60872-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Effect modification by population dietary folate on the association between <italic>MTHFR</italic> genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Holmes</surname>
            <given-names>Michael V</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="fn1" ref-type="fn">‡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Newcombe</surname>
            <given-names>Paul</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">f</xref>
          <xref rid="aff7" ref-type="aff">g</xref>
          <xref rid="fn1" ref-type="fn">‡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hubacek</surname>
            <given-names>Jaroslav A</given-names>
          </name>
          <xref rid="aff8" ref-type="aff">h</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sofat</surname>
            <given-names>Reecha</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ricketts</surname>
            <given-names>Sally L</given-names>
          </name>
          <xref rid="aff9" ref-type="aff">i</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cooper</surname>
            <given-names>Jackie</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Breteler</surname>
            <given-names>Monique MB</given-names>
          </name>
          <xref rid="aff14" ref-type="aff">n</xref>
          <xref rid="aff15" ref-type="aff">o</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bautista</surname>
            <given-names>Leonelo E</given-names>
          </name>
          <xref rid="aff16" ref-type="aff">p</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sharma</surname>
            <given-names>Pankaj</given-names>
          </name>
          <xref rid="aff17" ref-type="aff">q</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Whittaker</surname>
            <given-names>John C</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">f</xref>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smeeth</surname>
            <given-names>Liam</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fowkes</surname>
            <given-names>F Gerald R</given-names>
          </name>
          <xref rid="aff18" ref-type="aff">r</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Algra</surname>
            <given-names>Ale</given-names>
          </name>
          <xref rid="aff19" ref-type="aff">s</xref>
          <xref rid="aff22" ref-type="aff">v</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shmeleva</surname>
            <given-names>Veronika</given-names>
          </name>
          <xref rid="aff20" ref-type="aff">t</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Szolnoki</surname>
            <given-names>Zoltan</given-names>
          </name>
          <xref rid="aff21" ref-type="aff">u</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Roest</surname>
            <given-names>Mark</given-names>
          </name>
          <xref rid="aff23" ref-type="aff">w</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Linnebank</surname>
            <given-names>Michael</given-names>
          </name>
          <xref rid="aff24" ref-type="aff">x</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zacho</surname>
            <given-names>Jeppe</given-names>
          </name>
          <xref rid="aff25" ref-type="aff">y</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nalls</surname>
            <given-names>Michael A</given-names>
          </name>
          <xref rid="aff26" ref-type="aff">z</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Singleton</surname>
            <given-names>Andrew B</given-names>
          </name>
          <xref rid="aff26" ref-type="aff">z</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferrucci</surname>
            <given-names>Luigi</given-names>
          </name>
          <xref rid="aff27" ref-type="aff">aa</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hardy</surname>
            <given-names>John</given-names>
          </name>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Worrall</surname>
            <given-names>Bradford B</given-names>
          </name>
          <xref rid="aff28" ref-type="aff">ab</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rich</surname>
            <given-names>Stephen S</given-names>
          </name>
          <xref rid="aff29" ref-type="aff">ac</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matarin</surname>
            <given-names>Mar</given-names>
          </name>
          <xref rid="aff4" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Norman</surname>
            <given-names>Paul E</given-names>
          </name>
          <xref rid="aff30" ref-type="aff">ad</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Flicker</surname>
            <given-names>Leon</given-names>
          </name>
          <xref rid="aff31" ref-type="aff">ae</xref>
          <xref rid="aff34" ref-type="aff">ah</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Osvaldo P</given-names>
          </name>
          <xref rid="aff32" ref-type="aff">af</xref>
          <xref rid="aff34" ref-type="aff">ah</xref>
          <xref rid="aff35" ref-type="aff">ai</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van Bockxmeer</surname>
            <given-names>Frank M</given-names>
          </name>
          <xref rid="aff33" ref-type="aff">ag</xref>
          <xref rid="aff36" ref-type="aff">aj</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shimokata</surname>
            <given-names>Hiroshi</given-names>
          </name>
          <xref rid="aff37" ref-type="aff">ak</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Khaw</surname>
            <given-names>Kay-Tee</given-names>
          </name>
          <xref rid="aff10" ref-type="aff">j</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wareham</surname>
            <given-names>Nicholas J</given-names>
          </name>
          <xref rid="aff11" ref-type="aff">k</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bobak</surname>
            <given-names>Martin</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sterne</surname>
            <given-names>Jonathan AC</given-names>
          </name>
          <xref rid="aff39" ref-type="aff">am</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>George Davey</given-names>
          </name>
          <xref rid="aff38" ref-type="aff">al</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Talmud</surname>
            <given-names>Philippa J</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van Duijn</surname>
            <given-names>Cornelia</given-names>
          </name>
          <xref rid="aff14" ref-type="aff">n</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Humphries</surname>
            <given-names>Steve E</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Price</surname>
            <given-names>Jackie F</given-names>
          </name>
          <xref rid="aff18" ref-type="aff">r</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ebrahim</surname>
            <given-names>Shah</given-names>
          </name>
          <xref rid="aff6" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lawlor</surname>
            <given-names>Debbie A</given-names>
          </name>
          <xref rid="aff38" ref-type="aff">al</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hankey</surname>
            <given-names>Graeme J</given-names>
          </name>
          <xref rid="aff31" ref-type="aff">ae</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meschia</surname>
            <given-names>James F</given-names>
          </name>
          <xref rid="aff40" ref-type="aff">an</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sandhu</surname>
            <given-names>Manjinder S</given-names>
          </name>
          <xref rid="aff12" ref-type="aff">l</xref>
          <xref rid="aff13" ref-type="aff">m</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hingorani</surname>
            <given-names>Aroon D</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Casas</surname>
            <given-names>Juan P</given-names>
          </name>
          <email>juan.pablo-casas@lshtm.ac.uk</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="aff6" ref-type="aff">f</xref>
          <xref rid="cor1" ref-type="corresp">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Research Department of Epidemiology and Public Health, University College London, London, UK</aff>
      <aff id="aff2"><label>b</label>Department of Clinical Pharmacology, University College London, London, UK</aff>
      <aff id="aff3"><label>c</label>Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, London, UK</aff>
      <aff id="aff4"><label>d</label>Department of Clinical and Experimental Epilepsy, University College London, London, UK</aff>
      <aff id="aff5"><label>e</label>Institute of Neurology, University College London, London, UK</aff>
      <aff id="aff6"><label>f</label>Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, UK</aff>
      <aff id="aff7"><label>g</label>Genetics, R&amp;D, GlaxoSmithKline, Stevenage, UK</aff>
      <aff id="aff8"><label>h</label>Institute for Clinical and Experimental Medicine and Centre for Cardiovascular Research, Prague, Czech Republic</aff>
      <aff id="aff9"><label>i</label>Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK</aff>
      <aff id="aff10"><label>j</label>Clinical Gerontology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK</aff>
      <aff id="aff11"><label>k</label>MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK</aff>
      <aff id="aff12"><label>l</label>Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK</aff>
      <aff id="aff13"><label>m</label>Genetic Epidemiology Group, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Cambridge, UK</aff>
      <aff id="aff14"><label>n</label>Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, Netherlands</aff>
      <aff id="aff15"><label>o</label>German Centre for Neurodegenerative diseases (DZNE), Bonn, Germany</aff>
      <aff id="aff16"><label>p</label>Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin at Madison, Madison, WI, USA</aff>
      <aff id="aff17"><label>q</label>Imperial College Cerebrovascular Research Unit (ICCRU), Imperial College London, London, UK</aff>
      <aff id="aff18"><label>r</label>Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK</aff>
      <aff id="aff19"><label>s</label>Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands</aff>
      <aff id="aff20"><label>t</label>Russian Institute of Haematology and Transfusion, St Petersburg, Russia</aff>
      <aff id="aff21"><label>u</label>Department of Neurology, Pandy County Hospital, Gyula, Hungary</aff>
      <aff id="aff22"><label>v</label>Utrecht Stroke Center, Department of Neurology, and Julius Center, University Medical Center Utrecht, Netherlands</aff>
      <aff id="aff23"><label>w</label>Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Netherlands</aff>
      <aff id="aff24"><label>x</label>Department of Neurology, University Hospital Zurich, Zurich, Switzerland</aff>
      <aff id="aff25"><label>y</label>Department of Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark</aff>
      <aff id="aff26"><label>z</label>Laboratory of Neurogenetics, National Institute on Aging, US National Institute of Health, Bethesda, MD, USA</aff>
      <aff id="aff27"><label>aa</label>National Institute on Aging, Baltimore, MD, USA</aff>
      <aff id="aff28"><label>ab</label>Department of Neurology, University of Virginia, Charlottesville, VA, USA</aff>
      <aff id="aff29"><label>ac</label>Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA</aff>
      <aff id="aff30"><label>ad</label>School of Surgery, University of Western Australia, Perth, WA, Australia</aff>
      <aff id="aff31"><label>ae</label>School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia</aff>
      <aff id="aff32"><label>af</label>School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, WA, Australia</aff>
      <aff id="aff33"><label>ag</label>School of Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australia</aff>
      <aff id="aff34"><label>ah</label>Western Australian Centre for Health and Ageing (WACHA), Western Australia Institute for Medical Research, Perth, WA, Australia</aff>
      <aff id="aff35"><label>ai</label>Department of Psychiatry, Royal Perth Hospital, Perth, WA, Australia</aff>
      <aff id="aff36"><label>aj</label>Cardiovascular Genetics Laboratory, Division of Laboratory Medicine, Royal Perth Hospital, Perth, WA, Australia</aff>
      <aff id="aff37"><label>ak</label>National Center for Geriatrics and Gerontology, Obu City, Japan</aff>
      <aff id="aff38"><label>al</label>MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol, UK</aff>
      <aff id="aff39"><label>am</label>School of Social and Community Medicine, University of Bristol, Bristol, UK</aff>
      <aff id="aff40"><label>an</label>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA</aff>
      <author-notes>
        <corresp id="cor1"><label>*</label>Correspondence to: Dr Juan P Casas, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK <email>juan.pablo-casas@lshtm.ac.uk</email></corresp>
        <fn id="fn1">
          <label>‡</label>
          <p>These authors contributed equally</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>13</day>
        <month>8</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <day>13</day>
        <month>8</month>
        <year>2011</year>
      </pub-date>
      <volume>378</volume>
      <issue>9791</issue>
      <fpage>584</fpage>
      <lpage>594</lpage>
      <permissions>
        <copyright-statement>© 2011 Elsevier Ltd. All rights reserved.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Summary</title>
        <sec>
          <title>Background</title>
          <p>The <italic>MTHFR</italic> 677C→T polymorphism has been associated with raised homocysteine concentration and increased risk of stroke. A previous overview showed that the effects were greatest in regions with low dietary folate consumption, but differentiation between the effect of folate and small-study bias was difficult. A meta-analysis of randomised trials of homocysteine-lowering interventions showed no reduction in coronary heart disease events or stroke, but the trials were generally set in populations with high folate consumption. We aimed to reduce the effect of small-study bias and investigate whether folate status modifies the association between <italic>MTHFR</italic> 677C→T and stroke in a genetic analysis and meta-analysis of randomised controlled trials.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>We established a collaboration of genetic studies consisting of 237 datasets including 59 995 individuals with data for homocysteine and 20 885 stroke events. We compared the genetic findings with a meta-analysis of 13 randomised trials of homocysteine-lowering treatments and stroke risk (45 549 individuals, 2314 stroke events, 269 transient ischaemic attacks).</p>
        </sec>
        <sec>
          <title>Findings</title>
          <p>The effect of the <italic>MTHFR</italic> 677C→T variant on homocysteine concentration was larger in low folate regions (Asia; difference between individuals with TT versus CC genotype, 3·12 μmol/L, 95% CI 2·23 to 4·01) than in areas with folate fortification (America, Australia, and New Zealand, high; 0·13 μmol/L, −0·85 to 1·11). The odds ratio (OR) for stroke was also higher in Asia (1·68, 95% CI 1·44 to 1·97) than in America, Australia, and New Zealand, high (1·03, 0·84 to 1·25). Most randomised trials took place in regions with high or increasing population folate concentrations. The summary relative risk (RR) of stroke in trials of homocysteine-lowering interventions (0·94, 95% CI 0·85 to 1·04) was similar to that predicted for the same extent of homocysteine reduction in large genetic studies in populations with similar folate status (predicted RR 1·00, 95% CI 0·90 to 1·11). Although the predicted effect of homocysteine reduction from large genetic studies in low folate regions (Asia) was larger (RR 0·78, 95% CI 0·68 to 0·90), no trial has evaluated the effect of lowering of homocysteine on stroke risk exclusively in a low folate region.</p>
        </sec>
        <sec>
          <title>Interpretation</title>
          <p>In regions with increasing levels or established policies of population folate supplementation, evidence from genetic studies and randomised trials is concordant in suggesting an absence of benefit from lowering of homocysteine for prevention of stroke. Further large-scale genetic studies of the association between <italic>MTHFR</italic> 677C→T and stroke in low folate settings are needed to distinguish effect modification by folate from small-study bias. If future randomised trials of homocysteine-lowering interventions for stroke prevention are undertaken, they should take place in regions with low folate consumption.</p>
        </sec>
        <sec>
          <title>Funding</title>
          <p>Full funding sources listed at end of paper (see Acknowledgments).</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="cesec10">
      <title>Introduction</title>
      <p>Prospective cohort studies previously estimated that, if causal, a reduction of 3 μmol/L in serum homocysteine would decrease risk of coronary heart disease by 18% and stroke by 24% after a mean follow-up of 7·3 years.<xref rid="bib1 bib2" ref-type="bibr"><sup>1,2</sup></xref> However, residual confounding and reverse causation are alternative non-causal explanations for the observational association.<xref rid="bib3 bib4" ref-type="bibr"><sup>3,4</sup></xref> Mendelian randomisation studies use genetic variants as proxies of non-genetic risk factors to assess whether a risk factor is causally related to a disease. The approach exploits the independent randomised assortment of maternal and paternal alleles at the time of gamete formation to reduce confounding, and the fixed nature of genotype to abolish reverse causality and minimise regression-dilution bias, which can affect the association of a non-genetic risk factor with disease.<xref rid="bib5 bib6 bib7" ref-type="bibr"><sup>5–7</sup></xref> Mendelian randomisation analyses have previously investigated the potential causal role of homocysteine in stroke<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> and coronary heart disease<xref rid="bib8 bib9" ref-type="bibr"><sup>8,9</sup></xref> using the <italic>MTHFR</italic> 677C→T variant (rs1801133) as a proxy for homocysteine concentration that is independent of other risk factors, and have provided support for a causal role of homocysteine in stroke.<xref rid="bib1 bib10" ref-type="bibr"><sup>1,10</sup></xref> However, literature-based genetic meta-analyses can be affected by small-study bias.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> For instance, in our previous mendelian randomisation analysis of <italic>MTHFR</italic> 677C→T,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> only two studies had more than 400 stroke cases.</p>
      <p>In addition to our original study, results of other studies<xref rid="bib11 bib12 bib13" ref-type="bibr"><sup>11–13</sup></xref> also suggest that the effect of the <italic>MTHFR</italic> 677C→T variant on homocysteine concentration could be modified by the prevailing concentrations of folic acid, with high folate being associated with a reduced effect of <italic>MTHFR</italic> 677C→T on homocysteine concentrations. This suggestion is further supported by evidence that low folate intake or concentrations are associated with increased stroke risk.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> This gene–environment interaction is biologically plausible because folic acid plays a central part in the metabolism of homocysteine. Similarly, effect modification of folic acid on the <italic>MTHFR</italic> 677C→T effect has also been suggested for colon cancer.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> If prevailing concentrations of folic acid do modify homocysteine concentration, established policies for folic acid fortification of cereals and flour in several countries, for the prevention of neural tube defects,<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> would also be expected to modify the association between <italic>MTHFR</italic> 677C→T and stroke risk. This effect would also modify the interpretation of published randomised clinical trials of homocysteine-lowering interventions for stroke prevention that have shown no reduction in stroke risk in meta-analysis,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> but trials to date have been predominantly set in populations with high folate consumption.</p>
      <p>To investigate the potential modifying effect of folate status on the association between the <italic>MTHFR</italic> 677C→T variant and stroke risk, we established a collaboration of genetic studies including data for homocysteine concentration and stroke events. We compared the findings of this updated genetic analysis with a meta-analysis of randomised controlled trials of homocysteine-lowering treatments on stroke risk.</p>
    </sec>
    <sec sec-type="methods" id="cesec20">
      <title>Methods</title>
      <sec id="cesec30">
        <title>Search strategy and selection criteria</title>
        <p><xref rid="sec1" ref-type="sec">Webappendix pp 1–7</xref> provides detailed information about methods used. We did a literature search in Medline up to August, 2010, to identify randomised controlled trials using homocysteine-lowering interventions that evaluated cardiovascular endpoints. Medline and Embase were searched up to January, 2008, for all studies of the association between the rs1801133 polymorphism (<italic>MTHFR</italic> 677C→T variant) and stroke. To minimise reporting and publication bias, we supplemented our database with unpublished data by contacting investigators who reported genetic findings in stroke or cardiovascular disease in peer-reviewed journals.</p>
      </sec>
      <sec id="cesec40">
        <title>Data extraction</title>
        <p>Data were extracted and entered into a database for randomised trials (MVH and JPC) and genetic studies (PN, MVH). Genetic studies were classified into five categories of probable folate status. Full details of this process (developed and validated by Robert Clarke, Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, UK) are provided on <xref rid="sec1" ref-type="sec">webappendix pp 1–7</xref>. In brief, Robert Clarke undertook a systematic review of population-based studies in adults that measured folic acid concentration or quantified folate intake from nutritional questionnaires. Information about geographical location of study, years of conduct, and regional folic acid fortification policies (including years in which policies were established, if relevant) were used to generate five categories approximating the probable folate status at the population level. Categories were sorted from lowest to highest probable folate status: (1) no fortification (Asia, north and sub-Saharan Africa); (2) low (prefortification in 1996: Europe, including Ireland, Scandinavia, the Netherlands, Russia, and Turkey); (3) mid (postfortification in 1996: Europe); (4) mid (prefortification: America, Australia, and New Zealand before 1996; Central and South America); (5) high postfortification (America, Australia, and New Zealand after 1996, Chile after 2000).</p>
      </sec>
      <sec id="cesec50">
        <title>Statistical analysis</title>
        <p>Statistical analysis followed guidelines from the HuGE Review Handbook for meta-analysis of genetic association studies<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> and the Cochrane Handbook for Systematic Reviews of Interventions.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> In all meta-analyses, the presence of small-study bias was investigated by funnel plot and Egger test.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Additionally, we attempted to quantify the potential effect of small-study bias by restricting the analysis to large studies only, using the trim-and-fill method,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> and estimating the number of null hypothetical studies that were needed to add to change the summary effect from the meta-analysis (see <xref rid="sec1" ref-type="sec">webappendix pp 1–7</xref> for further details).</p>
        <p>Random effect models (DerSimonian and Laird) were used to obtain the mean difference in concentrations of homocysteine according to <italic>MTHFR</italic> 677C→T genotype (CC, homozygous common allele; CT, heterozygous; and TT, homozygous rare allele). Individuals homozygous for the C allele were used as the reference group. We did an ad-hoc analysis to investigate whether differences in plasma folate by the <italic>MTHFR</italic> 677C→T variant were also modified by folate status category.</p>
        <p>We did a meta-analysis of published and unpublished genetic studies on stroke to obtain a per-genotype summary odds ratio (OR) and corresponding 95% CI (using random effect models, DerSimonian and Laird) for all stroke types combined, using individuals homozygous for the C allele as the reference group.</p>
        <p>To check for confounding, we used Genome-wide Linkage Disequilibrium Repository and Search engine (GLIDERS) software<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> to evaluate long-range linkage disequilibrium for the rs1801133 variant in different ethnic groups. We crosschecked retrieved single nucleotide polymorphisms (SNPs) in genome-wide association study repositories (NHGRI GWAS Catalog<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> and <ext-link ext-link-type="uri" xlink:href="http://www.snp-nexus.org">SNPnexus</ext-link>) to confirm or refute whether any of these variants were associated with stroke or a stroke-related trait (eg, blood pressure).</p>
        <p>Finally, we did a meta-analysis of randomised trials to estimate the effect of homocysteine-lowering treatment (ie, folic acid supplementation with or without additional B vitamins) on stroke risk in trials using placebo, low dose-folic acid, or usual care as the comparator group. We used the DerSimonian and Laird <italic>Q</italic> test in all meta-analyses to evaluate the degree of heterogeneity between studies, and the <italic>I</italic><sup>2</sup> measure to describe the proportion of total variation in study estimates attributable to heterogeneity.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></p>
      </sec>
      <sec id="cesec60">
        <title>Role of the funding source</title>
        <p>The funding sources had no role in study design, in the collection, analysis, and interpretation of data, in writing of the report, or in the decision to submit for publication. The corresponding author (JPC) had full access to all data in the study and had final responsibility for the decision to submit for publication.</p>
      </sec>
    </sec>
    <sec id="cesec70">
      <title>Results</title>
      <p>We established a collaboration of genetic studies consisting of 237 datasets, including 59 995 individuals with data for homocysteine and 20 885 stroke events. For analysis of homocysteine and the <italic>MTHFR</italic> 677C→T polymorphism, 98 datasets from 79 studies, including 59 995 individuals, met our selection criteria. 67 datasets (<xref rid="sec1" ref-type="sec">webappendix pp 18–19</xref>) including 53 643 participants without evidence of cardiovascular disease contributed to the analysis of the association between <italic>MTHFR</italic> 677C→T and homocysteine concentration. A histogram of sample sizes (<xref rid="sec1" ref-type="sec">webappendix p 8</xref>) and genotype frequencies according to folate status category and by ethnic group (<xref rid="sec1" ref-type="sec">webappendix p 9–10</xref>) are provided. Individuals from the remaining 31 datasets (of 98) were excluded because they had cardiovascular disease, which could affect the derived value of the gene variant on homocysteine concentrations.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> In individuals without cardiovascular disease, irrespective of probable folate status, the mean difference in homocysteine concentrations between those homozygous for the T allele compared with those homozygous for the C allele was 2·10 μmol/L (95% CI 1·71 to 2·50; <italic>I</italic><sup>2</sup>=83·5%). For heterozygous individuals, the mean difference in homocysteine concentration was 0·42 μmol/L (95% CI 0·30 to 0·54; <italic>I</italic><sup>2</sup>=49·3%) compared with those with the CC genotype.</p>
      <p>The <italic>MTHFR</italic> 677C→T effect on homocysteine was highly dependent on probable folate status category (<xref rid="fig1" ref-type="fig">figure 1</xref>). In regions with no supplementation with folic acid (Asia), participants homozygous for the T allele had higher concentrations of homocysteine (3·12 μmol/L, 95% CI 2·23 to 4·01) than did those homozygous for the C allele. The effect was reduced in studies undertaken in geographical regions with policies of folic acid fortification (America, Australia, and New Zealand, high: 0·13 μmol/L, 95% CI −0·85 to 1·11). When analysis was limited to large studies (≥500 individuals), similar results were obtained (<xref rid="fig1" ref-type="fig">figure 1</xref>). Patterns were similar when heterozygous individuals were compared with those homozygous for the C allele, although the magnitude of the genetic effect was smaller (<xref rid="fig1" ref-type="fig">figure 1</xref>).</p>
      <p>A metaregression analysis showed an inverse association between difference in homocysteine concentration by genotype (TT <italic>vs</italic> CC) and probable folate status category coded in ascending order of probable levels of folic acid status (Asia; Europe, low; Europe, mid; America, Australia, and New Zealand, mid; and America, Australia, and New Zealand, high), suggesting an interaction between <italic>MTHFR</italic> 677C→T variant and folate status. For a one-category increase in folate status, the genetic effect on homocysteine concentration was reduced by 0·62 μmol/L (95% CI 0·29 to 0·94). To explore possible effects of small-study bias, metaregression was restricted to only large studies (≥500 individuals) and a similar pattern was noted (β coefficient for a one-category increase was equal to a reduction in homocysteine of 0·54 μmol/L, 95% CI 0·05 to 1·03). In a subset of 35 studies totalling 12 007 participants with information about plasma folic acid concentration, metaregression analysis suggested that for every increase of 1 ng/mL in plasma folic acid concentration, the mean difference in homocysteine concentrations for TT individuals versus CC individuals decreased by 0·13 μmol/L (95% CI −0·01 to 0·28). The Egger regression test (which tests the null hypothesis that the funnel plot is symmetrical<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref>) coefficient was 0·79 (95% CI −0·10 to 1·69; p=0·08) for TT versus CC comparison, and 0·36 (95% CI −0·14 to 0·87; p=0·16) for the CT versus CC comparison (including all studies, irrespective of geographical location). By contrast with a clear effect of folate status category on the <italic>MTHFR</italic>–homocysteine association, the evidence from our subsample of studies with data for plasma folic acid concentration did not reveal a clear trend between <italic>MTHFR</italic> and plasma folic acid across probable folate categories (data not shown).</p>
      <p>140 datasets from 101 studies including 20 885 stroke events met our selection criteria and were included in the meta-analysis of <italic>MTHFR</italic> 677C→T polymorphism and stroke (<xref rid="sec1" ref-type="sec">webappendix pp 20–21</xref>). 94 datasets measured ischaemic stroke (17 909 cases), 20 haemorrhagic stroke (1615 cases), one silent brain infarction (161 cases), and 25 total stroke (6972 cases, including ischaemic and haemorrhagic cases, resulting in overlap between categories). Total stroke included studies that reported both haemorrhagic and ischaemic stroke and those that did not classify stroke because neuroimaging was unavailable. Of the studies that did not classify stroke, 17 were in individuals of European ancestry in whom most strokes are of ischaemic cause. Genotype frequencies according to folate status category and by ethnic origin are reported on <xref rid="sec1" ref-type="sec">webappendix p 11–12</xref>.</p>
      <p>The summary OR for the main stroke comparison irrespective of probable folate status category was 1·37 (95% CI 1·25 to 1·50; <italic>I</italic><sup>2</sup>=48·4%) for participants homozygous for the T allele compared with those homozygous for the C allele (<xref rid="sec1" ref-type="sec">webappendix p 13</xref>). The OR for heterozygous individuals was 1·14 (95% CI 1·08 to 1·21; <italic>I</italic><sup>2</sup>=43·4%). When restricted to large studies (≥400 stroke events), the OR was 1·09 (95% CI 0·98 to 1·20; <italic>I</italic><sup>2</sup>=24·6%) for TT individuals and 1·06 (95% CI 1·00 to 1·12; <italic>I</italic><sup>2</sup>=0·0%) for CT individuals compared with those homozygous for the C allele. Results for different stroke subtypes followed a similar pattern (<xref rid="sec1" ref-type="sec">webappendix p 13</xref>).</p>
      <p>In regions without folic acid fortification (Asia),<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> the odds of stroke was 1·68 (95% CI 1·44 to 1·97) for comparison of individuals with the TT genotype and those with the CC genotype (<xref rid="fig2" ref-type="fig">figure 2</xref>). This increase in risk was substantially larger than that noted in regions with low folate intake (Europe, low: OR 1·01, 95% CI 0·88 to 1·16) and regions with mid folate intake (Europe, mid: OR 1·33, 95% CI 1·14 to 1·55) or folate fortification (America, Australia, and New Zealand, high: OR 1·03, 95% CI 0·84 to 1·25). A similar pattern was reported in comparisons of heterozygous (CT) individuals and those with the CC genotype (<xref rid="fig2" ref-type="fig">figure 2</xref>).</p>
      <p>To examine the effect of small-study bias on the association between <italic>MTHFR</italic> TT versus CC in Asia and risk of stroke, we first restricted our analysis to studies with 400 or more stroke events, which yielded an OR of 1·28 (95% CI 1·11 to 1·48; <xref rid="fig3" ref-type="fig">figure 3</xref>).<xref rid="bib26 bib27 bib28 bib29 bib30 bib31 bib32 bib33 bib34 bib35 bib36 bib37 bib38" ref-type="bibr"><sup>26–38</sup></xref> We then did a trim-and-fill analysis that, after taking into consideration the number and outcomes of potentially missing data, provided an adjusted summary OR equal to 1·30 (95% CI 1·19 to 1·43; <xref rid="sec1" ref-type="sec">webappendix p 14</xref>), which was concordant with the point estimate derived from our analysis restricted to large studies. Last, we undertook a sensitivity analysis to estimate the effect on the point estimate of the OR for stroke risk in Asian studies (for the <italic>MTHFR</italic> TT <italic>vs</italic> CC comparison) from the sequential addition of hypothetical large and null studies of 400 stroke cases and 400 controls with equal distribution according to expected <italic>MTHFR</italic> C/T genotype frequencies in Asian ancestry (<xref rid="sec1" ref-type="sec">webappendix pp 4–5</xref>). We estimated that 41 such studies would be needed to reduce the overall point estimate from OR 1·68 to 1·15 (the threshold at which cumulative evidence in genetic studies would be downgraded on the basis of Venice criteria<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref>) and 260 such studies to reduce the lower bound of the 95% CI to 1·00; other hypothetical scenarios are reported on <xref rid="sec1" ref-type="sec">webappendix p 22</xref>. Furthermore, genetic studies of <italic>MTHFR</italic> and stroke from Asia contributed as many stroke cases as did other geographical regions, with no major differences in the mean allele frequency for the <italic>MTHFR</italic> C/T variant (<xref rid="sec1" ref-type="sec">webappendix pp 9–12</xref>).</p>
      <p>A metaregression analysis showed that for a shift from one folate status category to the next highest category, the OR for stroke decreased by 10% (95% CI 1 to 18) for the TT versus CC comparison and 6% (95% CI 1 to 12) for the CT versus CC comparison. In a subsample of 25 studies (6266 stroke events) with information about both stroke and homocysteine concentration, the OR for the TT versus CC genotype tended to increase as the difference in homocysteine concentration by genotype increased: from 1·28 (95% CI 0·96 to 1·71) for studies with the smallest difference in homocysteine (bottom tertile) to 1·67 (95% CI 1·18 to 2·35) in studies with the largest difference in homocysteine (top tertile). However, there was substantial overlap in the confidence intervals by category and the metaregression analysis p value was 0·34. No trend was noted for heterozygous individuals (<xref rid="sec1" ref-type="sec">webappendix p 15</xref>).</p>
      <p>When we included all studies, the coefficient for the Egger test was 1·15 (95% CI 0·65 to 1·64; p&lt;0·0001) for TT versus CC and 0·90 (95% CI 0·37 to 1·42) for CT versus CC (p=0·001). Since this finding could be attributable to differences in the genotypic effect by folate categories (suggested in <xref rid="fig1" ref-type="fig">figure 1</xref> and <xref rid="fig3" ref-type="fig">figure 3</xref>), we ran the Egger test in studies from each geographical region separately. The respective coefficients for the Egger test were (for TT <italic>vs</italic> CC comparisons) 1·20 (95% CI 0·48 to 1·92; p=0·002) for Asia; 0·51 (95% CI −0·55 to 1·57; p=0·318) for Europe, low; 1·08 (95% CI 0·02 to 2·15; p=0·046) for Europe, mid; 2·91 (95% CI −2·42 to 8·24; p=0·143) for America, Australia, and New Zealand, mid; and 1·29 (95% CI −1·59 to 4·17; p=0·250) for America, Australia, and New Zealand, high.</p>
      <p>Apart from being a signal in genome-wide association studies for homocysteine,<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> we did not find reports of an association of the rs1801133 (<italic>MTHFR</italic> 677T) variant with established risk factors for stroke, or for any SNPs in linkage disequilibrium with it (defined as <italic>r</italic><sup>2</sup>&gt;0·3) (<xref rid="sec1" ref-type="sec">webappendix p 23</xref>). Although one SNP in <italic>MTHFR</italic> (rs17367504) was identified as a genome-wide association study locus for systolic blood pressure,<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> the linkage disequilibrium between rs17367504 and rs1801133 is low (<italic>r</italic><sup>2</sup> 0·09 European and Asian, 0·01 African ancestry; 1000 Genomes Project Pilot 1) and is unlikely to account for the association between rs1801133 and stroke.</p>
      <p>13 randomised trials of homocysteine-lowering interventions including 45 549 individuals (2314 stroke events and 269 transient ischaemic attacks) met our selection criteria for analysis of <italic>MTHFR</italic> 677C→T and stroke in the context of randomised trials of homocysteine-lowering interventions (<xref rid="sec1" ref-type="sec">webappendix p 24</xref>).<xref rid="bib42 bib43 bib44 bib45 bib46 bib47 bib48 bib49 bib50 bib51 bib52 bib53 bib54" ref-type="bibr"><sup>42–54</sup></xref> Trials identified included mainly participants with vascular disease (coronary heart disease or stroke), chronic kidney disease, or diabetes. We identified no trials exclusively set in low folate regions (Asia) that fulfilled our selection criteria. The main outcome for analysis consisted of both fatal and non-fatal ischaemic or haemorrhagic stroke and the weighted mean follow-up duration was 4·7 years (range 2–7·3 years).</p>
      <p>Active treatment resulted in a mean reduction in homocysteine concentration of 3·33 μmol/L (24% proportionate reduction) and a relative risk of stroke of 0·94 (95% CI 0·85 to 1·04; <italic>I</italic><sup>2</sup>=18·8%; <xref rid="fig4" ref-type="fig">figure 4</xref>). Metaregression analyses of the log of the relative risk for stroke against the mean net or proportional reduction in homocysteine achieved by the intervention, or against the probable folate status category, did not show an association (p&gt;0·5). With the probable exception of HOPE-2,<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> no trial had an undue effect on the estimate of the pooled relative risk (<xref rid="sec1" ref-type="sec">webappendix p 16</xref>). A subgroup analysis did not reveal major differences of the intervention on stroke by prespecified study-level characteristic, with the possible exceptions of sample size and risk of bias (<xref rid="fig5" ref-type="fig">figure 5</xref>).</p>
      <p>When we compared the effect from randomised trials undertaken in non-Asian populations to the effect of large genetic studies in the same population, a concordance of no reduction in risk of stroke was noted: relative risk reduction 6% (95% CI −4 to 15) and 0% (95% CI −11 to 10), respectively (<xref rid="fig4" ref-type="fig">figure 4</xref>). The relative risk reduction suggested by large Asian genetic studies of 22% (95% CI 10–32) could not be directly compared with interventional trials because no randomised trial has been done exclusively in these regions.</p>
    </sec>
    <sec id="cesec80">
      <title>Discussion</title>
      <p>The <italic>MTHFR</italic> 677C→T variant was associated with a larger effect on homocysteine concentration in regions of low folate consumption than in regions with high dietary folate intake or with established programmes of folic acid fortification of flour for prevention of neural tube defects. A similar pattern was noted for the genetic association with stroke risk. However, even though our analysis is less likely to be affected by small-study bias than was our previous meta-analysis,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> whether this difference reflects modification of the genetic association with stroke risk by population folate consumption or small-study bias remains unclear (<xref rid="box1" ref-type="boxed-text">panel</xref>).</p>
      <p>Even if the evidence of an increased risk of stroke associated with the <italic>MTHFR</italic> 677C→T variant is robust, reduction of homocysteine concentration might not necessarily reverse the risk of stroke in adult life. Such evidence can only be derived from randomised trials of interventions such as folic acid that reduce the concentration of homocysteine. Our meta-analysis of randomised trials evaluating homocysteine-lowering treatments in stroke showed a non-significant reduction in the risk of stroke of 6% (95% CI −4 to 15). We note, however, that with the exception of half the participants from the VITATOPS trial who were recruited from low folate regions (Asia), the rest of the participants (n=41 467, 91%) included in trials to date were from regions with high concentrations of folic acid or with established policies of folic acid fortification. The point estimate derived from the randomised trials was, however, concordant with that predicted from large genetic studies (≥400 stroke events) undertaken outside Asia (0% risk reduction; 95% CI −11 to 10; <xref rid="fig4" ref-type="fig">figure 4</xref>). The concordance of results, showing no benefit on stroke prevention from randomised trials and large genetic studies in non-Asian populations, suggests that homocysteine-lowering treatments in populations already fortified or with increasing population levels of folic acid might not provide additional benefit in reduction of the risk of stroke. Similar triangulation of genetic studies and randomised trials undertaken in low folate regions was hampered by the scarcity of evidence from randomised trials set in such regions (only 9% of all randomised trial participants). Nonetheless, the predicted risk reduction in stroke of 22% (95% CI 10 to 32) derived from large genetic studies in low folate regions suggests that if an adequately powered randomised trial were to be done in Asia, homocysteine reduction might have a substantial protective effect on stroke. However, our data also suggest that we cannot reliably exclude that the effect of the <italic>MTHFR</italic> 677C→T variant on stroke reported in large genetic studies done in low folate regions is attributable to other mechanisms different from lowering of homocysteine, or to small-study bias.</p>
      <p>By contrast with our genetic meta-analyses, the estimate from randomised trials did not seem to be affected by the reduction in homocysteine achieved or by probable folate status of the population studied. However, this analysis was based on study-level characteristics, and thus the power to detect real differences with only 13 studies (as opposed to 101 genetic studies) was restricted, and the proportional reduction of homocysteine concentrations for most trials was fairly similar (median 26%, range 8–31), with the exception of one very small trial<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> that achieved a 44% reduction. Nonetheless, a previous meta-analysis<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> of homocysteine reduction and vascular events found no evidence of heterogeneity when stratifying by pretreatment or percentage reduction of plasma homocysteine or by regional folate fortification. Furthermore, the VITATOPS trial<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> did not find evidence that individuals of Asian origin had a different effect from homocysteine reduction than did other individuals.</p>
      <p>A few differences between the evidence obtained from randomised trials and genetic studies are important to emphasise. First, as already mentioned, most trial evidence arose from settings in which policies of folic acid fortification have already been implemented (ie, America, Australia, and New Zealand) or in which folate concentrations at the population level have been increasing in recent years.<xref rid="bib16 bib56" ref-type="bibr"><sup>16,56</sup></xref> By contrast, around 40% of stroke events in the genetic studies that we analysed are from unfortified regions or populations with low concentrations of folate (Asia or Europe, low). Second, despite the extent of reduction in homocysteine concentrations being largely similar across the genetic studies and randomised trials (3·33 μmol/L for trials and 2·58 μmol/L for large genetic studies), the length of follow-up was substantially different. Randomised trials had a weighted average follow-up of 4·7 years and allocation to the intervention occurred in middle age (mean age range 56–69 years). By contrast, genetic studies reflect lifetime exposure to the phenotype resulting from the genetic variant, since randomisation to the allele variants occurs at conception. Third, the number of stroke events in trials is substantially lower than that included in the genetic analyses (2314 stroke events in trials <italic>vs</italic> 20 885 events in genetic studies), thus the meta-analysis of randomised trials had fairly low statistical power to detect small benefits or those noted mainly in a subgroup (eg, low folate regions). Fourth, evidence from randomised trials is derived mainly from individuals with established vascular disease, whereas that from genetic studies is mainly population-based. Therefore, genetic evidence should be regarded only as an approximate guide to the risk reduction that could be achieved by modification of homocysteine concentrations in randomised trials.</p>
      <p>Although mendelian randomisation analysis reduces biases and confounding seen in non-genetic observational studies, it can still be prone to small-study bias and confounding by linkage disequilibrium. Our in-silico analysis evaluating the long-range linkage disequilibrium of the <italic>MTHFR</italic> 677C→T variant, used as an instrument for homocysteine, suggests that the differential genetic results by folate regions are unlikely to arise by differences in linkage disequilibrium between folate regions. To minimise the effect of small-study bias, we made great efforts to rescue data from unpublished studies and undertook, at the analytical stage, several sensitivity analyses that attempted to quantify the effect of small studies. First, restriction of the analysis to studies with at least 400 cases yielded an OR of 1·28 (95% CI 1·11 to 1·48; <xref rid="fig3" ref-type="fig">figure 3</xref>). Second, taking into account the number and potential outcome of missing data in a trim-and-fill analysis resulted in an adjusted summary OR of 1·30 (95% CI 1·19 to 1·43; <xref rid="sec1" ref-type="sec">webappendix p 14</xref>). Finally, using the observed distribution of <italic>MTHFR</italic> C/T genotypes, we estimated that 41 additional null studies with 400 cases and 400 controls each would be needed to reduce the overall OR from 1·68 to 1·15, the threshold OR at which cumulative evidence would be deemed questionable on the basis of Venice criteria<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> (<xref rid="sec1" ref-type="sec">webappendix pp 4–5, 22</xref>). However, these analyses cannot wholly adjust for potential small-study bias<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> and residual bias might persist, which emphasises the need for verification of the findings in large genetic studies undertaken in low folate regions.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref></p>
      <p>We used the <italic>MTHFR</italic> 677C→T variant as a genetic instrument to evaluate the effects of homocysteine on disease risk; however, the poor specificity of this variant (a situation inherent for trans variants used as instruments of non-protein traits)<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> makes it possible that the genetic effect of <italic>MTHFR</italic> could be by a mechanism other than homocysteine.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> The use of probable folate status categories represents an estimate of population average with the possibility of substantial variability of natural folate intake within each category. This approach could underestimate the effect of folate status categories on homocysteine concentration and stroke risk. By contrast, the use of categories of probable folate status instead of folate concentrations from individual participants creates the possibility that the effect of the <italic>MTHFR</italic> variant by categories of population folate levels could be due to a strong association with another factor causally involved in the development of stroke. However, the plausibility of <italic>MTHFR</italic>–folic acid interaction is supported by the CARDIA study,<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref> which showed that the effect of the <italic>MTHFR</italic> variant on homocysteine concentration is modified by participant folate concentrations, and that such effect is largely diminished after the establishment of a policy of folic acid fortification. Finally, the effect seen in low folate regions could be due to selective reporting bias in the subtype of stroke reported in genetic case-control or cohort studies—ie, if stroke subtype was differentially reported according to continent and was associated with <italic>MTHFR</italic> genotype, the observed signal could be inflated. In an attempt to minimise this bias, we contacted authors of all studies and asked for full details of all stroke subtypes, including unpublished data. Furthermore, when we examined the subtypes of stroke contributing to our main stroke outcome, there was general consistency in stroke subtype by folate region, with the exception of America, Australia, and New Zealand, mid (in which all strokes included were ischaemic). However, we cannot exclude the presence of selective outcome reporting bias that could affect our results.</p>
      <p>In conclusion, the concordance of findings on the genetic effects of <italic>MTHFR</italic> on homocysteine concentrations and the genetic association with stroke risk argues in favour of effect modification by prevailing folate concentrations in the population. If correct, this genetic finding would have important repercussions for the interpretation of clinical trials of homocysteine-lowering interventions. The effect of homocysteine-lowering interventions on stroke might be expected to be null in regions with high dietary folate intake or where food is fortified with folate, but it could be substantial in low folate regions such as Asia. Since stroke rates are high in Asian countries and the population at risk in Asia is very large, the public health benefit could be of great importance.<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> Unfortunately, the evidence from randomised trials undertaken in low folate settings is scarce and genetic studies in the same settings have tended to be smaller than those in high folate settings, leaving a potential that estimates of the genetic effect have been inflated. To resolve uncertainty about whether the association of the <italic>MTHFR</italic> variant with stroke risk in Asian studies is a consequence of small-study bias, low folate consumption in that region, or both, a large genetic study of stroke in a low folate region would be needed.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> If further trials are to be done to evaluate the efficacy of homocysteine-lowering interventions for stroke prevention, these should be undertaken in regions of low folate consumption. The ongoing China Stroke Primary Prevention Trial (CSPT)<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> is investigating 15 000 hypertensive individuals without established cardiovascular disease who are being randomly assigned to enalapril or enalapril plus folic acid and followed up for 5 years for development of the primary outcome, stroke. The addition of CSPT to the existing but small-scale evidence from randomised trials in low folate regions should yield a more definitive answer on the role (if any) of folic acid supplementation and lowering of homocysteine in prevention of stroke.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wald</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Law</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis</article-title>
          <source>BMJ</source>
          <volume>325</volume>
          <year>2002</year>
          <fpage>1202</fpage>
          <pub-id pub-id-type="pmid">12446535</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Homocysteine Studies Collaboration</collab>
          </person-group>
          <article-title>Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis</article-title>
          <source>JAMA</source>
          <volume>288</volume>
          <year>2002</year>
          <fpage>2015</fpage>
          <lpage>2022</lpage>
          <pub-id pub-id-type="pmid">12387654</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brattstrom</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wilcken</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine and cardiovascular disease: cause or effect?</article-title>
          <source>Am J Clin Nutr</source>
          <volume>72</volume>
          <year>2000</year>
          <fpage>315</fpage>
          <lpage>323</lpage>
          <pub-id pub-id-type="pmid">10919920</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ueland</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Refsum</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Beresford</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Vollset</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>The controversy over homocysteine and cardiovascular risk</article-title>
          <source>Am J Clin Nutr</source>
          <volume>72</volume>
          <year>2000</year>
          <fpage>324</fpage>
          <lpage>332</lpage>
          <pub-id pub-id-type="pmid">10919921</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davey Smith</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ebrahim</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?</article-title>
          <source>Int J Epidemiol</source>
          <volume>32</volume>
          <year>2003</year>
          <fpage>1</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="pmid">12689998</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hingorani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Humphries</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Nature's randomised trials</article-title>
          <source>Lancet</source>
          <volume>366</volume>
          <year>2005</year>
          <fpage>1906</fpage>
          <lpage>1908</lpage>
          <pub-id pub-id-type="pmid">16325682</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheehan</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Didelez</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Burton</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Tobin</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Mendelian randomisation and causal inference in observational epidemiology</article-title>
          <source>PLoS Med</source>
          <volume>5</volume>
          <year>2008</year>
          <fpage>e177</fpage>
          <pub-id pub-id-type="pmid">18752343</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klerk</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Verhoef</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Clarke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Blom</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Kok</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Schouten</surname>
              <given-names>EG</given-names>
            </name>
          </person-group>
          <article-title>MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis</article-title>
          <source>JAMA</source>
          <volume>288</volume>
          <year>2002</year>
          <fpage>2023</fpage>
          <lpage>2031</lpage>
          <pub-id pub-id-type="pmid">12387655</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lewis</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Ebrahim</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Davey Smith</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?</article-title>
          <source>BMJ</source>
          <volume>331</volume>
          <year>2005</year>
          <fpage>1053</fpage>
          <pub-id pub-id-type="pmid">16216822</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Casas</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bautista</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Smeeth</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hingorani</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine and stroke: evidence on a causal link from mendelian randomisation</article-title>
          <source>Lancet</source>
          <volume>365</volume>
          <year>2005</year>
          <fpage>224</fpage>
          <lpage>232</lpage>
          <pub-id pub-id-type="pmid">15652605</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hustad</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Midttun</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Schneede</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vollset</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Grotmol</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ueland</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>The methylenetetrahydrofolate reductase 677C→T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism</article-title>
          <source>Am J Hum Genet</source>
          <volume>80</volume>
          <year>2007</year>
          <fpage>846</fpage>
          <lpage>855</lpage>
          <pub-id pub-id-type="pmid">17436239</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chiuve</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Giovannucci</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Hankinson</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>Alcohol intake and methylenetetrahydrofolate reductase polymorphism modify the relation of folate intake to plasma homocysteine</article-title>
          <source>Am J Clin Nutr</source>
          <volume>82</volume>
          <year>2005</year>
          <fpage>155</fpage>
          <lpage>162</lpage>
          <pub-id pub-id-type="pmid">16002814</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Bree</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Verschuren</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Bjorke-Monsen</surname>
              <given-names>AL</given-names>
            </name>
          </person-group>
          <article-title>Effect of the methylenetetrahydrofolate reductase 677C→T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample</article-title>
          <source>Am J Clin Nutr</source>
          <volume>77</volume>
          <year>2003</year>
          <fpage>687</fpage>
          <lpage>693</lpage>
          <pub-id pub-id-type="pmid">12600862</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Merchant</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rimm</surname>
              <given-names>EB</given-names>
            </name>
          </person-group>
          <article-title>Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men</article-title>
          <source>Stroke</source>
          <volume>35</volume>
          <year>2004</year>
          <fpage>169</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="pmid">14671243</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sharp</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Little</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brockton</surname>
              <given-names>NT</given-names>
            </name>
          </person-group>
          <article-title>Polymorphisms in the methylenetetrahydrofolate reductase (<italic>MTHFR</italic>) gene, intakes of folate and related B vitamins and colorectal cancer: a case-control study in a population with relatively low folate intake</article-title>
          <source>Br J Nutr</source>
          <volume>99</volume>
          <year>2008</year>
          <fpage>379</fpage>
          <lpage>389</lpage>
          <pub-id pub-id-type="pmid">18053312</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eichholzer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tönz</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Folic acid: a public-health challenge</article-title>
          <source>Lancet</source>
          <volume>367</volume>
          <year>2006</year>
          <fpage>1352</fpage>
          <lpage>1361</lpage>
          <pub-id pub-id-type="pmid">16631914</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Demirtas</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of folic acid supplementation in stroke prevention: a meta-analysis</article-title>
          <source>Lancet</source>
          <volume>369</volume>
          <year>2007</year>
          <fpage>1876</fpage>
          <lpage>1882</lpage>
          <pub-id pub-id-type="pmid">17544768</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <mixed-citation publication-type="other">Little J, Higgins J, eds. HuGE review handbook. <ext-link ext-link-type="uri" xlink:href="http://www.hugenet.org.uk/resources/handbook.php">http://www.hugenet.org.uk/resources/handbook.php</ext-link> (accessed April 11, 2010).</mixed-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <mixed-citation publication-type="other">Higgins J, Green S, eds. Cochrane handbook for systematic reviews of interventions, version 5.0.2. The Cochrane Collaboration 2009. <ext-link ext-link-type="uri" xlink:href="http://www.cochrane-handbook.org">www.cochrane-handbook.org</ext-link> (accessed April 11, 2010).</mixed-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Davey Smith</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Minder</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>
          <source>BMJ</source>
          <volume>315</volume>
          <year>1997</year>
          <fpage>629</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="pmid">9310563</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duval</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tweedie</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis</article-title>
          <source>Biometrics</source>
          <volume>56</volume>
          <year>2000</year>
          <fpage>455</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="pmid">10877304</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lawrence</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Day-Williams</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Mott</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Broxholme</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cardon</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Zeggini</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>GLIDERS—a web-based search engine for genome-wide linkage disequilibrium between HapMap SNPs</article-title>
          <source>BMC Bioinformatics</source>
          <volume>10</volume>
          <year>2009</year>
          <fpage>367</fpage>
          <pub-id pub-id-type="pmid">19878600</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <name>
              <surname>Hindorff</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Junkins</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Manolio</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>A catalog of published genome-wide association studies</article-title>
          <ext-link ext-link-type="uri" xlink:href="http://www.genome.gov/gwastudies">www.genome.gov/gwastudies</ext-link>
          <comment>(accessed April 30, 2010).</comment>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higgins</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Deeks</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Altman</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>Measuring inconsistency in meta-analyses</article-title>
          <source>BMJ</source>
          <volume>327</volume>
          <year>2003</year>
          <fpage>557</fpage>
          <lpage>560</lpage>
          <pub-id pub-id-type="pmid">12958120</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ling</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>National neural tube defects prevention program in China</article-title>
          <source>Food Nutr Bull</source>
          <volume>29</volume>
          <issue>2 suppl</issue>
          <year>2008</year>
          <fpage>S196</fpage>
          <lpage>S204</lpage>
          <pub-id pub-id-type="pmid">18709893</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Somarajan</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Kalita</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mittal</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Misra</surname>
              <given-names>UK</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of MTHFR C677T polymorphism in ischemic and hemorrhagic stroke patients. A case–control study in a Northern Indian population</article-title>
          <source>J Neurol Sciences</source>
          <volume>304</volume>
          <year>2011</year>
          <fpage>67</fpage>
          <lpage>70</lpage>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>XL</given-names>
            </name>
          </person-group>
          <article-title>Relationship between methylenetrahydrofolate reductase gene and ischemic stroke</article-title>
          <source>Chin Crit Care Med</source>
          <volume>18</volume>
          <year>2006</year>
          <fpage>264</fpage>
          <lpage>267</lpage>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Metoki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Genetic risk for ischemic and hemorrhagic stroke</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>26</volume>
          <year>2006</year>
          <fpage>1920</fpage>
          <lpage>1925</lpage>
          <pub-id pub-id-type="pmid">16741147</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Multicenter Case-Control Study in China. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a multicenter case-control study in China</article-title>
          <source>Stroke</source>
          <volume>34</volume>
          <year>2003</year>
          <fpage>2085</fpage>
          <lpage>2090</lpage>
          <pub-id pub-id-type="pmid">12907815</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hofman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Breteler</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>van Duijn</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>The Rotterdam Study: 2010 objectives and design update</article-title>
          <source>Eur J Epidemiol</source>
          <volume>24</volume>
          <year>2009</year>
          <fpage>553</fpage>
          <lpage>572</lpage>
          <pub-id pub-id-type="pmid">19728115</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frederiksen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Juul</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Grande</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study</article-title>
          <source>Blood</source>
          <volume>104</volume>
          <year>2004</year>
          <fpage>3046</fpage>
          <lpage>3051</lpage>
          <pub-id pub-id-type="pmid">15226189</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kostulas</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Brophy</surname>
              <given-names>VH</given-names>
            </name>
            <name>
              <surname>Moraitis</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Genetic profile of ischemic cerebrovascular disease and carotid stenosis</article-title>
          <source>Acta Neurol Scand</source>
          <volume>118</volume>
          <year>2008</year>
          <fpage>146</fpage>
          <lpage>152</lpage>
          <pub-id pub-id-type="pmid">18325076</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szolnoki</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Havasi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bene</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Endothelial nitric oxide synthase gene interactions and the risk of ischaemic stroke</article-title>
          <source>Acta Neurol Scand</source>
          <volume>111</volume>
          <year>2005</year>
          <fpage>29</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="pmid">15595935</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lalouschek</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Endler</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schillinger</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Candidate genetic risk factors of stroke: results of a multilocus genotyping assay</article-title>
          <source>Clin Chem</source>
          <volume>53</volume>
          <year>2007</year>
          <fpage>600</fpage>
          <lpage>605</lpage>
          <pub-id pub-id-type="pmid">17317888</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Day</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Oakes</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Luben</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer</article-title>
          <source>Br J Cancer</source>
          <volume>80</volume>
          <issue>suppl 1</issue>
          <year>1999</year>
          <fpage>95</fpage>
          <lpage>103</lpage>
          <pub-id pub-id-type="pmid">10466767</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Szolnoki</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Somogyvari</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kondacs</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke</article-title>
          <source>J Neurol Neurosurg Psychiatry</source>
          <volume>74</volume>
          <year>2003</year>
          <fpage>1615</fpage>
          <lpage>1620</lpage>
          <pub-id pub-id-type="pmid">14638877</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meschia</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Brott</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>RD</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>The Ischemic Stroke Genetics Study (ISGS) protocol</article-title>
          <source>BMC Neurol</source>
          <volume>3</volume>
          <year>2003</year>
          <fpage>4</fpage>
          <pub-id pub-id-type="pmid">12848902</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meschia</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>RD</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Brott</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Chukwudelunzu</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>The Siblings With Ischemic Stroke Study (SWISS) protocol</article-title>
          <source>BMC Med Genet</source>
          <volume>3</volume>
          <year>2002</year>
          <fpage>1</fpage>
          <pub-id pub-id-type="pmid">11882254</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ioannidis</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Boffetta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Little</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Assessment of cumulative evidence on genetic associations: interim guidelines</article-title>
          <source>Int J Epidemiol</source>
          <volume>37</volume>
          <year>2008</year>
          <fpage>120</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">17898028</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pare</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chasman</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>AN</given-names>
            </name>
          </person-group>
          <article-title>Novel associations of <italic>CPS1</italic>, <italic>MUT</italic>, <italic>NOX4</italic>, and <italic>DPEP1</italic> with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women's Genome Health Study</article-title>
          <source>Circ Cardiovasc Genet</source>
          <volume>2</volume>
          <year>2009</year>
          <fpage>142</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="pmid">20031578</pub-id>
        </element-citation>
      </ref>
      <ref id="bib41">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Newton-Cheh</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gateva</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Genome-wide association study identifies eight loci associated with blood pressure</article-title>
          <source>Nat Genet</source>
          <volume>41</volume>
          <year>2009</year>
          <fpage>666</fpage>
          <lpage>676</lpage>
          <pub-id pub-id-type="pmid">19430483</pub-id>
        </element-citation>
      </ref>
      <ref id="bib42">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liem</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Reynierse-Buitenwerf</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Zwinderman</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Jukema</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>van Veldhuisen</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Secondary prevention with folic acid: results of the Goes extension study</article-title>
          <source>Heart</source>
          <volume>91</volume>
          <year>2005</year>
          <fpage>1213</fpage>
          <lpage>1214</lpage>
          <pub-id pub-id-type="pmid">16103563</pub-id>
        </element-citation>
      </ref>
      <ref id="bib43">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ebbing</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bleie</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ueland</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial</article-title>
          <source>JAMA</source>
          <volume>300</volume>
          <year>2008</year>
          <fpage>795</fpage>
          <lpage>804</lpage>
          <pub-id pub-id-type="pmid">18714059</pub-id>
        </element-citation>
      </ref>
      <ref id="bib44">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonaa</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Njolstad</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ueland</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine lowering and cardiovascular events after acute myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <volume>354</volume>
          <year>2006</year>
          <fpage>1578</fpage>
          <lpage>1588</lpage>
          <pub-id pub-id-type="pmid">16531614</pub-id>
        </element-citation>
      </ref>
      <ref id="bib45">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Righetti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Serbelloni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Milani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ferrario</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients</article-title>
          <source>Blood Purif</source>
          <volume>24</volume>
          <year>2006</year>
          <fpage>379</fpage>
          <lpage>386</lpage>
          <pub-id pub-id-type="pmid">16755160</pub-id>
        </element-citation>
      </ref>
      <ref id="bib46">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armitage</surname>
              <given-names>JM</given-names>
            </name>
            <collab>on behalf of the SEARCH Study Collaborative Group</collab>
          </person-group>
          <article-title>Late-breaking clinical trial abstracts from the American Heart Association's Scientific Sessions 2008. Abstract S165: SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine): randomized comparison of folic acid 2 mg plus vitamin b12 1 mg daily versus placebo for 7 years in 12 064 myocardial infarction survivors</article-title>
          <source>Circulation</source>
          <volume>118</volume>
          <year>2008</year>
          <fpage>2310</fpage>
        </element-citation>
      </ref>
      <ref id="bib47">
        <label>47</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>The VITATOPS Trial Study Group</collab>
          </person-group>
          <article-title>B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial</article-title>
          <source>Lancet Neurol</source>
          <volume>9</volume>
          <year>2010</year>
          <fpage>855</fpage>
          <lpage>865</lpage>
          <pub-id pub-id-type="pmid">20688574</pub-id>
        </element-citation>
      </ref>
      <ref id="bib48">
        <label>48</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lonn</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Yusuf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Arnold</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine lowering with folic acid and B vitamins in vascular disease</article-title>
          <source>N Engl J Med</source>
          <volume>354</volume>
          <year>2006</year>
          <fpage>1567</fpage>
          <lpage>1577</lpage>
          <pub-id pub-id-type="pmid">16531613</pub-id>
        </element-citation>
      </ref>
      <ref id="bib49">
        <label>49</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>House</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Eliasziw</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cattran</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial</article-title>
          <source>JAMA</source>
          <volume>303</volume>
          <year>2010</year>
          <fpage>1603</fpage>
          <lpage>1609</lpage>
          <pub-id pub-id-type="pmid">20424250</pub-id>
        </element-citation>
      </ref>
      <ref id="bib50">
        <label>50</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zoungas</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>McGrath</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Branley</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial</article-title>
          <source>J Am Coll Cardiol</source>
          <volume>47</volume>
          <year>2006</year>
          <fpage>1108</fpage>
          <lpage>1116</lpage>
          <pub-id pub-id-type="pmid">16545638</pub-id>
        </element-citation>
      </ref>
      <ref id="bib51">
        <label>51</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wrone</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Hornberger</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Zehnder</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>McCann</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Coplon</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Fortmann</surname>
              <given-names>SP</given-names>
            </name>
          </person-group>
          <article-title>Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease</article-title>
          <source>J Am Soc Nephrol</source>
          <volume>15</volume>
          <year>2004</year>
          <fpage>420</fpage>
          <lpage>426</lpage>
          <pub-id pub-id-type="pmid">14747389</pub-id>
        </element-citation>
      </ref>
      <ref id="bib52">
        <label>52</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jamison</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Hartigan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kaufman</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
          <article-title>Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial</article-title>
          <source>JAMA</source>
          <volume>298</volume>
          <year>2007</year>
          <fpage>1163</fpage>
          <lpage>1170</lpage>
          <pub-id pub-id-type="pmid">17848650</pub-id>
        </element-citation>
      </ref>
      <ref id="bib53">
        <label>53</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Albert</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Gaziano</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial</article-title>
          <source>JAMA</source>
          <volume>299</volume>
          <year>2008</year>
          <fpage>2027</fpage>
          <lpage>2036</lpage>
          <pub-id pub-id-type="pmid">18460663</pub-id>
        </element-citation>
      </ref>
      <ref id="bib54">
        <label>54</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toole</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Malinow</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Chambless</surname>
              <given-names>LE</given-names>
            </name>
          </person-group>
          <article-title>Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial</article-title>
          <source>JAMA</source>
          <volume>291</volume>
          <year>2004</year>
          <fpage>565</fpage>
          <lpage>575</lpage>
          <pub-id pub-id-type="pmid">14762035</pub-id>
        </element-citation>
      </ref>
      <ref id="bib55">
        <label>55</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Halsey</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lewington</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals</article-title>
          <source>Arch Intern Med</source>
          <volume>170</volume>
          <year>2010</year>
          <fpage>1622</fpage>
          <lpage>1631</lpage>
          <pub-id pub-id-type="pmid">20937919</pub-id>
        </element-citation>
      </ref>
      <ref id="bib56">
        <label>56</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Armitage</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lewington</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis</article-title>
          <source>Clin Chem Lab Med</source>
          <volume>45</volume>
          <year>2007</year>
          <fpage>1575</fpage>
          <lpage>1581</lpage>
          <pub-id pub-id-type="pmid">18265450</pub-id>
        </element-citation>
      </ref>
      <ref id="bib57">
        <label>57</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Cohort profile: the Kadoorie Study of Chronic Disease in China (KSCDC)</article-title>
          <source>Int J Epidemiol</source>
          <volume>34</volume>
          <year>2005</year>
          <fpage>1243</fpage>
          <lpage>1249</lpage>
          <pub-id pub-id-type="pmid">16131516</pub-id>
        </element-citation>
      </ref>
      <ref id="bib58">
        <label>58</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Drenos</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Talmud</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Casas</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk</article-title>
          <source>Hum Mol Genet</source>
          <volume>18</volume>
          <year>2009</year>
          <fpage>2305</fpage>
          <lpage>2316</lpage>
          <pub-id pub-id-type="pmid">19336475</pub-id>
        </element-citation>
      </ref>
      <ref id="bib59">
        <label>59</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stern</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Selhub</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>SW</given-names>
            </name>
          </person-group>
          <article-title>Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene</article-title>
          <source>Cancer Epidemiol Biomarkers Prev</source>
          <volume>9</volume>
          <year>2000</year>
          <fpage>849</fpage>
          <lpage>853</lpage>
          <pub-id pub-id-type="pmid">10952104</pub-id>
        </element-citation>
      </ref>
      <ref id="bib60">
        <label>60</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Loria</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Polygenic association with total homocysteine in the post-folic acid fortification era: the CARDIA study</article-title>
          <source>Mol Genet Metab</source>
          <volume>98</volume>
          <year>2009</year>
          <fpage>181</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="pmid">19577940</pub-id>
        </element-citation>
      </ref>
      <ref id="bib61">
        <label>61</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strong</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mathers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bonita</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Preventing stroke: saving lives around the world</article-title>
          <source>Lancet Neurol</source>
          <volume>6</volume>
          <year>2007</year>
          <fpage>182</fpage>
          <lpage>187</lpage>
          <pub-id pub-id-type="pmid">17239805</pub-id>
        </element-citation>
      </ref>
      <ref id="bib62">
        <label>62</label>
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <collab>China Stroke Primary Prevention Trial (CSPPT)</collab>
          </person-group>
          <article-title>NCT00794885</article-title>
          <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00794885">http://clinicaltrials.gov/ct2/show/NCT00794885</ext-link>
          <comment>(accessed December, 2010).</comment>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="sec1">
      <title>Web Extra Material</title>
      <p>
        <supplementary-material content-type="local-data" id="ecomp10">
          <caption>
            <title>Supplementary webappendix</title>
          </caption>
          <media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/>
        </supplementary-material>
      </p>
    </sec>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Robert Clarke, Sarah Parish, and Derrick A Bennett (Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, UK) for their insightful comments and advice; Barbara Voetsch, Yiingdong Zhang, Nina Salooja, Myeong-Kyu Kim, Hugh Markus, Ahamad Hassan, Koichi Miyaki, Jose Maria Grasa Ullrich, Belen Sanchez, Hui Rutai, Emel Gurkan, Nam Keun Kim, Tomohiro Katsuya, Ravindra Varma Alluri, Renu Saxena, Larry Baum, Kostantinos Kostulas, Fahri Ucar, Ali Sazci, Byung-Ok Choi, Yan Zhen Zheng, Christine Mannhalter, Rossella Marcucci, Alessandro Pezzini, John Eikelboom, Xin Fang, Lise Lotte Husemoen, and Hiroki Namba for providing relevant information about the genotype frequencies, homocysteine, and folic acid concentrations from their studies; and Dave Leon for his valuable comments on the report.</p>
      <p>Funding for this study was from: a Population Health Scientist Fellowship, Medical Research Council (G0802432; MVH); the Medical Research Council (G0600580; PN); Project 00023001 (IKEM; JAH); British Heart Foundation (Schillingford) clinical training fellowship (FS/07/011; RS); British Heart Foundation (SLR, JFP); Erasmus Medical Center and Erasmus University, Rotterdam, The Netherlands Organization for Health Research and Development, The Netherlands Organisation for Scientific Research, the Research Institute for Diseases in the Elderly, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam (The Rotterdam Study; MMMB, CVD); UK Department of Health Senior Fellowship (PS); Senior Clinical Fellowship from the Wellcome Trust (082178, LS); British Heart Foundation (Edinburgh Artery Study, FGRF); the Netherlands Heart Foundation (2001.06g) and the Brain Foundation Netherlands (gF01.15; the RATIO Study; AA); the Danish Medical Research Council, the Danish Heart Foundation, and Chief Physician Johan Boserup and Lise Boserup's Fund (JZ); the US National Institute of Neurological Disorders and Stroke, grant numbers R01 NS39987 and R01 NS42733 (ISGS and SWISS: MAN, ABS, LF, JH, BBW, SR, MM, JFM); Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services (LF; project numbers Z01 AG000015-50 and Z01 AG000954-06, human subjects protocol number 2003-078; portions of this study used the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health); Research Funding for Longevity Sciences (23–33) from the National Center for Geriatrics and Gerontology, Japan (HS); the National Health and Medical Research Council of Australia (the Health In Men Study, project grants 279408, 379600, 403963, and 513823; PEN, LF, OA, FvB, GH); Wellcome Trust and the US National Institute of Aging (the HAPIEE study; MB); the UK Medical Research Council (G0600705) and the University of Bristol (GDS and DAL); British Heart Foundation Chair of Cardiovascular Genetics (SD); British Heart Foundation Senior Fellowship (FS05/125; ADH); British Heart Foundation (RG/08/008; SEH, PJT, ADH); and the Department of Health Policy Research Programme and British Heart Foundation (the British Women's Heart and Health Study; SE). The views expressed in the publication are those of the authors and not necessarily those of any funding bodies.</p>
    </ack>
    <ack>
      <title>Contributors</title>
      <p>JPC and ADH were responsible for the original study idea. JAH, SLR, JC, MMBB, PS, FGRF, AA, VS, ZS, MR, ML, JZ, MAN, ABS, LFe, JH, BBW, SSR, MM, PEN, LFl, OPA, FMvB, HS, KTK, NJW, MB, GDS, PJT, CvD, SEH, JFP, SE, DAL, GJH, JFM, and MSS provided detailed limited tabular data or unpublished data. MVH, PN, LEB, JCW, RS, LS, JACS, ADH, and JPC contributed to data collation, analyses, and interpretation. All authors contributed to manuscript drafting.</p>
    </ack>
    <ack>
      <title>Conflicts of interest</title>
      <p>PN is a full-time employee of GlaxoSmithKline. PS has received honoraria for lecturing in industry-sponsored meetings and has received industry funding for attending national and international meetings. He has also received research grants from pharmaceutical companies and has been a paid consultant to the biotech industry and a member of industry advisory boards. JCW owns shares in GlaxoSmithKline and is 90% employed at GlaxoSmithKline while retaining a 10% appointment at the London School of Hygiene and Tropical Medicine. LS has received consultancy fees from GlaxoSmithKline. FGRF has received funding from AstraZeneca for consultancy and grants from Bayer. AA received fees from Boehringer Ingelheim for consultancy, speaker fees, and participation in international advisory board meetings. He is a principal investigator of ESPIRIT, the European/Australian Stroke Prevention in Reversible Ischaemia Trial, a trial that was run independently of any pharmaceutical company, and in 2006, after completion and full analysis of ESPRIT, the study group accepted financial support from Boehringer Ingelheim for post-hoc exploratory analyses of the ESPRIT trial data. For this purpose a contract was signed in negotiated complete scientific freedom. ML has received money for board membership, consultancy, expert testimony, grants, and lectures from various pharmaceutical companies. JH has received consultancy fees from Merck Serono, Eisai, and Johnson &amp; Johnson. BBW is co-principal investigator of the NIH funded GARNET, which funds genome-wide association studies of genetic samples from the Vitamin Intervention as Stroke Prevention randomised controlled trial. GH has received funds from Johnson &amp; Johnson (executive committee for ROCKET-AF trial); Sanofi-Aventis (executive committee BOREALIS trial); Schering-Plough (steering committee TRA 2P TIMI 50 trial); Pradaxa (dabigatran) advisory board, Australia; and payment for lectures at sponsored scientific symposia by Sanofi-Aventis and Pfizer.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Figure 1</label>
      <caption>
        <p>Difference in homocysteine concentration in individuals without cardiovascular disease according to <italic>MTHFR</italic> 677C→T genotype, by probable folate status category</p>
        <p>Large studies are those with more than 500 individuals. AANZ=America, Australia, and New Zealand.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Figure 2</label>
      <caption>
        <p>Odds ratio of stroke according to <italic>MTHFR</italic> 677C→T variant, by probable folate status category</p>
        <p>Left panel compares individuals homozygous for T allele with CC participants. Right panel compares heterozygous with CC individuals. AANZ=America, Australia, and New Zealand.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>Figure 3</label>
      <caption>
        <p>Odds ratio of stroke in large studies (≥400 stroke events) according to <italic>MTHFR</italic> 677C→T genotype, by probable folate status category</p>
        <p>Differences in homocysteine concentration (derived from large studies; <xref rid="fig1" ref-type="fig">figure 1</xref>) are shown in category subheadings.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="fig4">
      <label>Figure 4</label>
      <caption>
        <p>Pooled relative risk of stroke from randomised clinical trials of homocysteine-lowering interventions in the context of genetic studies of the MTFHR 677C→T variant</p>
        <p>RCT=randomised controlled trials. AANZ=America, Australia, and New Zealand.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="fig5">
      <label>Figure 5</label>
      <caption>
        <p>Sensitivity analyses of effect of homocysteine-lowering interventions from randomised clinical trials on risk of stroke</p>
        <p>All analyses are random effects (DerSimonian and Laird). Number of clinical events reports stroke only as default and stroke plus TIA when specified in row title. RCT=randomised controlled trial. TIA=transient ischaemic attack. *Studies with fewer than 1000 participants were Wrone,<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> Zoungas,<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Liem,<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> Righetti,<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> and House.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> †<xref rid="sec1" ref-type="sec">See webappendix p 24</xref> for classification of risk of bias per study. ‡Studies reporting stroke and TIA separately were Righetti,<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> Wrone,<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> and HOPE-2.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> §Studies that used B vitamins (other than folic acid) as one of the comparator groups were Ebbing<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> and Bonaa;<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> studies that used low-dose folic acid as comparator group (and not placebo or standard care) were Wrone<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> and Toole.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref></p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <boxed-text id="box1">
      <label>Panel</label>
      <caption>
        <title>Research in context</title>
      </caption>
      <p>
        <bold>Systematic review</bold>
      </p>
      <p>Observational studies have shown an association between circulating concentrations of homocysteine and risk of stroke; however, these findings might arise from confounding or reverse causation, or both. Variants in <italic>MTHFR</italic> 677C→T (rs1801133), used as a non-confounded proxy of homocysteine exposure, have confirmed this association in previous meta-analysis; however, the magnitude of association differed by geographical location. This finding suggests that the association between homocysteine and stroke risk might be modified by prevailing folate intake, but another explanation could be small-study bias. Furthermore, findings from meta-analysis of randomised controlled trials investigating homocysteine-lowering interventions in stroke have been null.</p>
      <p>
        <bold>Interpretation</bold>
      </p>
      <p>The effects of <italic>MTHFR</italic> 677C→T on homocysteine decreased as the prevailing level of folic acid increased. These effects were mirrored in the analysis of <italic>MTHFR</italic> 677C→T and stroke: an association between <italic>MTHFR</italic> 677C→T and stroke was only evident in a region associated with low levels of folate, findings that were preserved in large studies. In regions with increasing levels of folate or with established policies of folic acid supplementation, the effect of <italic>MTHFR</italic> 677C→T on stroke was null. These findings argue in favour of a gene–environment interaction. When we attempted to frame findings from <italic>MTHFR</italic> genetic studies within the context of homocysteine-lowering randomised trials evaluating risk of stroke, randomised trials were predominantly undertaken in regions with existing folic acid supplementation, which could potentially account for the null summary estimate of randomised trials, and hindered our comparison. Large genetic studies on stroke in regions with low folate levels are needed to confirm or refute our findings. If future trials of homocysteine-lowering interventions for stroke risk are to be undertaken, they should be set in low folate regions.</p>
    </boxed-text>
  </floats-group>
</article>